Multidisciplinary Journal of Science and Technology

INTEGRATED THERAPEUTIC STRATEGIES AND PERSONALIZED APPROACHES IN THE MANAGEMENT OF LUMINAL B HER2-NEGATIVE BREAST CANCER: A CLINICAL-STATISTICAL ANALYSIS

Alimbayeva Sevara

Master of General Oncology, Tashkent Medical Academy (Tashkent State Medical University)

Axadullayev Dilmurod

Master of General Oncology, Tashkent Medical Academy (Tashkent State Medical University)

Madaminov Akhmadjan

PhD (K.M.N.), Republican Specialized Scientific-Practical Medical Center of Children's Hematology and Oncology

Keywords: Breast cancer, Luminal B, Neoadjuvant chemotherapy, Ki-67, Clinical Oncology, Biostatistics, Personalized Medicine.

---

Abstract

Breast cancer (BC) remains a leading cause of female morbidity and mortality globally. Modern management has shifted from a "one-size-fits-all" approach to molecular-subtype-driven personalized therapy. This study evaluates the clinical efficacy of dose-dense neoadjuvant chemotherapy (NACT) combined with targeted hormonal maintenance in patients with Luminal B HER2-negative breast cancer (stages IIA-IIIB). Analyzing a cohort of 84 patients, we assessed the objective response rate (ORR) and the frequency of pathological complete response (pCR). Statistical analysis using Student's t-test and $\chi^2$ criteria demonstrated that the integration of taxane-based dose-dense regimens significantly improves surgical outcomes compared to standard FEC protocols ($p < 0.05$). The findings emphasize the necessity of tailoring systemic therapy based on Ki-67 proliferation indices and lymphovascular invasion markers to optimize long-term survival.

---

References

1. Harbeck, N., et al. (2019). Breast cancer. The Lancet, 394(10204), 1167-1185.

2. Loibl, S., et al. (2021). Neoadjuvant chemotherapy in breast cancer: Treatment of the breast and the axilla. Annals of Oncology.

3. Giordano, S. H. (2018). Breast Cancer Treatment Guidelines. JAMA Oncology.

4. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). (2023). Increasing the dose intensity of chemotherapy: a meta-analysis. The Lancet Oncology.

5. Cardoso, F., et al. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology.

6. Aliev, N. A., et al. (2021). Epidemiology of Oncological diseases in Uzbekistan. Central Asian Journal of Medicine.

7. Sparano, J. A., et al. (2018). Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. New England Journal of Medicine.

8. Goldhirsch, A., et al. (2017). Personalizing the treatment of women with early breast cancer. Annals of Oncology.